In closing......I would like to state that the company remains focussed on commercializing the next standard of care treatment for BCG-unresponsive non-muscle-invasive bladder cancer, which includes:
1 - being properly capitalized using various equity and debt instruments
2 - completing patient enrolment and provision of the primary study procedure by year end
3 - achieving BTD status from the FDA in 2024
4 - achieving Health Canada and FDA regulatory marketing approval by the end of 2026
5 - successfully partnering the technology in 2026
In addition the company plans to:
1 - commence phase 1 clinical studies for brain cancer, lung cancer & blood based cancers in 2025
2 - launch a clinical study using Rutherrin activated by Metformin
3 - research and develop a topical ointment for the treatment of herpes simplex lesions
4 - development of a vaccine for avian influenza and possibly monkey pox